Table 2.
Demographic and clinical characteristics in NMOSD-ON and non-NMOSD-ON patients
| NMOSD-ON (n = 19) | non-NMOSD-ON (n = 24) | t/Z | P-value | |
|---|---|---|---|---|
| Age (yr) | 48.95±11.46 | 44.50±10.71 | 1.312 | 0.197a |
| Gender (male/female) | 1/18 | 0/24 | – | 0.442b |
| Education level (yr) | 9.95±2.74 | 10.42±2.93 | –0.365 | 0.715c |
| Right handedness | 19 | 24 | – | |
| AQP4 antibody (positive/negative) | 16/3 | 23/1 | – | 0.306b |
| EDSS score at the time of MRI | 2.34±1.93 | 2.04±1.75 | –0.659 | 0.510c |
| Disease duration (mon) | 48.66±58.77 | 31.04±44.29 | –0.722 | 0.470c |
| DSST | 38.86±12.05 | 41.73±13.39 | –0.617 | 0.537c |
| TMT-A | 70.38±19.06 | 64.62±31.91 | –1.363 | 0.173c |
| TMT-B | 171.48±51.38 | 157.06±68.29 | 0.676 | 0.504a |
Seven patients with NMOSD failed to complete the cognitive tests including the DSST, TMT-A, and TMT-B. Data were analyzed by two-sample t-test (a), Fisher’s exact test (b), or Mann-Whitney U test (c). AQP4: Aquaporin-4; DSST: Digit Symbol Substitution Test; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; NMOSD: neuromyelitis optica spectrum disorder; NMOSD-ON: NMOSD patients who experienced at least one clinical episode of optic neuritis; non-NMOSD-ON: NMOSD patients without clinical episodes of optic neuritis; TMT-A: Trail Making Test Subscale A; TMT-B: Trail Making Test Subscale B.